GlassScriptPhysician profile
Alexander S Kim
NPI 1841429404
$12,930.68
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
See the full distribution for Clinical & Laboratory Immunology (Allergy & Immunology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $61.35 · 2022: $370 · 2023: $543 · 2024: $286 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,645 · Travel and Lodging: $1,646 · Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,645.00 |
| Travel and Lodging | $1,646.01 |
| Food and Beverage | $1,326.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $10,527.08 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $456.39 | 2020-2025 | Cuvitru, Hyqvia |
| Shire North American Group INC | $279.67 | 2019 | |
| Blueprint Medicines Corporation | $263.96 | 2023-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $247.46 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $241.21 | 2019 | |
| Pharming Healthcare, INC. | $213.43 | 2022-2023 | Ruconest |
| Abbott Laboratories | $195.69 | 2023-2024 | Aveir, Perclose Prostyle |
| Glaxosmithkline, LLC. | $144.06 | 2019-2023 | Nucala |
| Optinose US, INC. | $113.85 | 2019 | |
| Genentech USA, INC. | $113.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.46 | 2025 | |
| Genzyme Corporation | $31.83 | 2023 | |
| Alexion Pharmaceuticals, INC. | $25.23 | 2024 | Ultomiris |
| Bio Products Laboratory USA, INC. | $15.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.